TYROSINES(1234-1235) ARE CRITICAL FOR ACTIVATION OF THE TYROSINE KINASE ENCODED BY THE MET PROTOONCOGENE (HGF RECEPTOR)

被引:3
|
作者
LONGATI, P [1 ]
BARDELLI, A [1 ]
PONZETTO, C [1 ]
NALDINI, L [1 ]
COMOGLIO, PM [1 ]
机构
[1] UNIV TORINO,SCH MED,DEPT BIOMED SCI & OCOL,I-10126 TURIN,ITALY
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The tyrosine kinase encoded by the MET proto-oncogene (p190(MET)) is the receptor for Hepatocyte Growth Factor/Scatter Factor (HGF/SF). Previous work has shown that autophosphorylation of p190(MET) enhances its enzymatic activity and that the major phosphorylation site is Tyr(1235), located in the catalytic domain. This residue is part of a 'three tyrosine' motif, including Tyr(1230), Tyr(1234), and Tyr(1235), conserved in several other receptor kinases. We studied the role of these tyrosines in the positive regulation of the p190(MET) kinase by site-directed mutagenesis. Substitution of either Tyr(1235) Or Tyr(1234) with phenylalanine severely reduced the in vitro kinase activity toward exogenous substrates. Kinetic experiments showed that the residual activity of these mutants could still be enhanced by autophosphorylation. Phosphopeptide mapping indicated that, in the absence of Tyr(1235), Tyr(1234) is phosphorylated. Only the replacement of both Tyr(1234) and Tyr(1235) yielded a mutant which completely lost the ability to be activated by autophosphorylation. In stable transfectants expressing the HGF/SF receptor with single substitution of either Tyr(1234) Or Tyr(1235) the response to HGF/SF was impaired. The ligand did not induce tyrosine phosphorylation of the receptor nor stimulated chemotaxis. These data show that Tyr(1234) and Tyr(1235) are critical for the activation of the HGF/SF receptor kinase both in vitro and in response to the ligand in intact cells.
引用
收藏
页码:49 / 57
页数:9
相关论文
共 50 条
  • [21] Identification of the receptor tyrosine kinase c-Met and its ligand, HGF, as therapeutic targets in clear cell sarcoma
    Davis, I.
    Coxon, A.
    Goldberg, J.
    Burgess, T.
    Fisher, D.
    EJC SUPPLEMENTS, 2006, 4 (12): : 187 - 187
  • [22] Role of the activation loop tyrosines in regulation of the insulin-like growth factor I receptor-tyrosine kinase
    Li, Wanqing
    Miller, W. Todd
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (33) : 23785 - 23791
  • [23] The Role of MET Activation in Determining the Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Rho, Jin Kyung
    Choi, Yun Jung
    Lee, Jin Kyung
    Ryoo, Baek-Yeol
    Na, Im Il
    Yang, Sung Hyun
    Lee, Seung Sook
    Kim, Cheol Hyeon
    Do Yoo, Young
    Lee, Jae Cheol
    MOLECULAR CANCER RESEARCH, 2009, 7 (10) : 1736 - 1743
  • [24] The hepatocyte growth factor (HGF)-MET receptor tyrosine kinase signaling pathway: Diverse roles in modulating immune cell functions
    Ilangumaran, Subburaj
    Villalobos-Hernandez, Alberto
    Bobbala, Diwakar
    Ramanathan, Sheela
    CYTOKINE, 2016, 82 : 125 - 139
  • [25] Listeria surface protein InlB mimics HGF-triggered endocytic trafficking of the receptor tyrosine kinase c-Met
    Li, N
    Ireton, K
    Elferink, LA
    MOLECULAR BIOLOGY OF THE CELL, 2004, 15 : 78A - 78A
  • [26] Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr–Met, involves exclusion from the endocytic degradative pathway
    H H L Mak
    P Peschard
    T Lin
    M A Naujokas
    D Zuo
    M Park
    Oncogene, 2007, 26 : 7213 - 7221
  • [27] Combined Targeting of the MET and FGF Receptor Tyrosine Kinases Induces Sustained AML Cell Death by Preventing Compensatory Upregulation of HGF in Response to MET Kinase Inhibition
    Kentsis, Alex
    Sanda, Takaomi
    Reed, Casie
    Rodig, Scott J.
    Tholouli, Eleni
    Vu Ngo
    Kutok, Jeffery Lorne
    Dahlberg, Suzanne E.
    Moreau, Lisa A.
    Woude, George Vande
    Christensen, James
    Byers, Richard
    Kung, Andrew L.
    Staudt, Louis M.
    Look, Thomas
    BLOOD, 2011, 118 (21) : 612 - 612
  • [28] Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays
    Srivastava, Apurva K.
    Hollingshead, Melinda G.
    Weiner, Jennifer
    Navas, Tony
    Evrard, Yvonne A.
    Khin, Sonny A.
    Ji, Jiuping Jay
    Zhang, Yiping
    Borgel, Suzanne
    Pfister, Thomas D.
    Kinders, Robert J.
    Bottaro, Donald P.
    Linehan, W. Marston
    Tomaszewski, Joseph E.
    Doroshow, James H.
    Parchment, Ralph E.
    CLINICAL CANCER RESEARCH, 2016, 22 (14) : 3683 - 3694
  • [29] Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway
    Mak, H. H. L.
    Peschard, P.
    Lin, T.
    Naujokas, M. A.
    Zuo, D.
    Park, M.
    ONCOGENE, 2007, 26 (51) : 7213 - 7221
  • [30] Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and map kinase activity in pancreatic cancer cells
    Qian, LW
    Mizumoto, K
    Inadome, N
    Nagai, E
    Sato, N
    Matsumoto, K
    Nakamura, T
    Tanaka, M
    INTERNATIONAL JOURNAL OF CANCER, 2003, 104 (05) : 542 - 549